With an estimated 30 million sufferers of obstructive sleep apnea, estimated to cost the US economy about $162bn, there is an urgent need to find an acceptable solution. During the 2018 Biotech Showcase, RespireRx Pharmaceuticals Inc. president & CEO James Manuso explained to Scrip how the company is repurposing an existing drug to tackle the problem.
Obstructive sleep apnea is a major unmet need. While CPAP devices are 100% effective in treating obstructive sleep apnea, only...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?